European perspective on the management of rheumatoid arthritis : clinical utility of tofacitinib by unknown
© 2018 Kawalec et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Therapeutics and Clinical Risk Management 2018:14 15–29
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
15
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TCRM.S138677
european perspective on the management of 
rheumatoid arthritis: clinical utility of tofacitinib
Paweł Kawalec1
Katarzyna Śladowska2
Iwona Malinowska-Lipień3
Tomasz Brzostek3
Maria Kózka4
1Drug Management Department, 
institute of Public Health, Faculty 
of Health Sciences, Jagiellonian 
University Medical College, 
2Department of experimental 
Hematology, institute of Zoology 
and Biomedical Research, Faculty 
of Biology and Earth Sciences, 
Jagiellonian University, Krakow, 
Poland; 3Department of internal 
and Community Nursing, institute 
of Nursing and Midwifery, Faculty 
of Health Sciences, Jagiellonian 
University Medical College, Krakow, 
Poland; 4Department of Clinical 
Nursing, institute of Nursing and 
Midwifery, Faculty of Health Sciences, 
Jagiellonian University Medical 
College, Krakow, Poland
Abstract: Xeljanz® (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits 
Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As 
a result of these mechanisms, effects on the immune system such as a moderate decrease in 
the total lymphocyte count, a dose-dependent decrease in natural killer (NK) cell count, and 
an increase in B-cell count have been observed. Therefore, tofacitinib provides an innovative 
approach to modulating the immune and inflammatory responses in patients with rheumatoid 
arthritis (RA), which is especially important in individuals who do not respond to tumor 
necrosis factor inhibitors or show a loss of response over time. The aim of this article was to 
review studies on the pharmacology, mode of action, pharmacokinetics, efficacy, and safety 
of tofacitinib in patients with RA. Tofacitinib has been shown to reduce symptoms of RA and 
improve the quality of life in the analyzed groups of patients. Moreover, it showed high efficacy 
and an acceptable safety profile in Phase III randomized clinical trials on RA and was the first 
JAK inhibitor approved by the US Food and Drug Administration (FDA) and European Medi-
cines Agency (EMA) in the RA therapy, thus providing a useful alternative treatment strategy. 
Randomized controlled studies revealed a significant benefit over placebo in efficacy outcomes 
(American College of Rheumatology [ACR] 20 and ACR50 response rates); accordingly, 
clinically meaningful improvements in patient-related outcomes compared with placebo have 
been reported. The safety profile seems acceptable, although some severe adverse effects have 
been observed, including serious infections, opportunistic infections (including tuberculosis 
and herpes zoster), malignancies, and cardiovascular events, which require strict monitoring 
irrespective of the duration of tofacitinib administration. As an oral drug, tofacitinib offers an 
alternative to subcutaneous or intravenous biologic drugs and should be recognized as a more 
convenient way of drug administration.
Keywords: JAK inhibitor, tofacitinib, effectiveness, rheumatoid arthritis, treatment
Introduction
RA is a chronic autoimmune inflammation of joints resulting in the severe destruction 
of cartilage and bones; the disease leads to severe disability, decreased quality of life, 
and reduced life expectancy;1–3 it occurs in ~1% of adults all over the world.1 Because 
RA is a chronic disease with potentially severe symptoms, therapy generates high 
health care utilization (direct costs) as well as productivity loss (indirect costs) over the 
lifetime of the disease as the onset of the condition is very often in young adults.2,4
The goal of treatment is to achieve remission or to slow down disease progres-
sion if remission is not possible; low disease activity is accepted as an important 
therapeutic goal.3,4
Response to RA therapy is often measured as American College of Rheumatology 
(ACR) scores (eg, ACR20 indicates that symptoms have improved 20% from baseline 
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and ACR50 means that they have improved 50%) or as 
improvement from the baseline European League Against 
Rheumatism (EULAR response) scale scores.3,5
T h e  c u r r e n t  t r e a t m e n t  o f  R A  i n c l u d e s 
nonsteroidal anti-inflammatory drugs (NSAIDs), corticos-
teroids, as well as disease-modifying antirheumatic drugs 
(DMARDs), including conventional DMARDs (methotrex-
ate [MTX], leflunomide, and sulfasalazine); the primary 
therapy in most patients is MTX, while individuals with 
poor response to MTX are often treated with subsequent 
drugs: biologic DMARDs such as tumor necrosis factor 
(TNF) inhibitors (infliximab, adalimumab, certolizumab 
pegol, etanercept, and golimumab), non-TNF biologics 
(abatacept, rituximab, and tocilizumab), and targeted syn-
thetic DMARDs (such as Janus-activated kinase [JAK] 
inhibitors including tofacitinib, baricitinib);6,7 alternative 
treatment option is a combination of TNF inhibitors with 
MTX; in a number of RA patients TNF inhibitors are 
combined with MTX.3 Biologic drugs essentially changed 
the current paradigm of therapy providing new treatment 
options; they reduce the symptoms and activity of the 
diseases and improve the quality of life in the case of 
patients not responsive to conventional DMARDs therapy.
Remission is achieved with DMARDs in 30%–40% of 
cases only, and 30% of the patients showed either insuf-
ficient response or lack of response to treatment with TNF 
inhibitors.6 The lack of efficacy (primary nonresponse) or 
the loss of efficacy over time (secondary nonresponse) and 
the safety profile issues make it difficult to find a drug that 
would offer long-lasting efficacy in a significant group of 
the RA patients.
According to the current research, 41%–58% of patients 
receiving TNF inhibitors do not achieve the ACR20 response, 
while other patients lose their clinical response or suffer from 
adverse events (AEs) during the therapy.8–10 Patients with an 
inadequate response or intolerance to conventional DMARDs 
are generally prescribed biologic DMARDs, usually in 
combination with MTX.11 Patients whose disease activity 
remains moderate or high with DMARD monotherapy are 
recommended to use a combination of DMARDs or to add a 
TNF inhibitor, a non-TNF biologic, or tofacitinib (all with or 
without MTX). For patients whose disease activity remains 
moderate or high despite the use of a single TNF inhibitor, 
the ACR conditionally recommends using a non-TNF bio-
logic over another TNF inhibitor (with or without MTX).3 
According to the EULAR guidelines on the use of biologics 
in RA, in all treatments, biologics should be combined 
preferentially with MTX or with other immunosuppressive 
agents; moreover, if the therapy targets have not been 
achieved with the first conventional DMARD strategy, it is 
necessary to add a biologic DMARD or a small synthetic 
molecule such as tofacitinib or baricitinib.7 Patients who 
do not respond adequately to treatment with TNF inhibitors 
are generally prescribed another drug of the same class or 
biologic DMARD with an alternative mechanism of action 
such as tocilizumab (interleukin [IL]-6 receptor antagonist), 
rituximab (monoclonal antibody against B cells), and abata-
cept (blocker of T-cell activation).7,12
In this review, we search PubMed database until August 
2017 to identify eligible English language trials evaluating 
the efficacy and safety of tofacitinib in RA patients. We 
analyzed randomized clinical trials, their extensions, and 
follow-up studies. For a more comprehensive assessment 
of the drug, an in-depth analysis of the safety profile was 
performed based on long-term extension (LTE) studies. The 
results of network meta-analyses (NMA) were also used to 
present the relative efficacy and safety of tofacitinib com-
pared with active reference treatments. Efficacy was assessed 
on the basis of standard endpoints used in RA (ACR20 and 
ACR50), while safety outcomes included the adverse effects 
reported with tofacitinib treatment. A difference with P0.05 
was considered as statistically significant.
Emerging treatment options
Despite a wide spectrum of current pharmacotherapies, new 
drugs such as secukinumab, ixekizumab, baricitinib, filgo-
tinib, peficitinib, and ocrelizumab have emerged, providing 
novel, promising treatment options.13,14
Secukinumab and ixekizumab are monoclonal antibod-
ies that selectively bind to and neutralize interleukin-17A 
(IL-17A), in which overexpression leads to inflammation, 
joint destruction, and bone erosion in RA.15,16 Secukinumab 
has been recently approved by the US Food and Drug Admin-
istration (FDA) for moderate-to-severe plaque psoriasis, 
psoriatic arthritis (PsA), and ankylosing spondylitis (AS). 
A Phase II trial demonstrated that secukinumab reduced the 
signs, symptoms, and activity of disease during a 24-week 
follow-up in patients with RA with poor response to TNF 
inhibitors.15 Another Phase II trial showed that ixekizumab 
significantly improved clinical signs and symptoms in 
patients with RA who were naive to biologic treatment or 
had shown inadequate response to TNF inhibitors during a 
12-week follow-up.16 Both secukinumab and ixekizumab had 
an acceptable safety profile.15,16
Other agents with promising results in Phase III or IIb 
studies include JAK inhibitors, such as baricitinib, filgotinib, 
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and peficitinib. Recent clinical trials have shown baricitinib 
to be a safe and effective drug in the RA patients who fail 
to respond to existing background therapy (including MTX) 
during 52 weeks of treatment.17 Satisfactory efficacy and 
safety results were also reported for peficitinib and filgo-
tinib monotherapies. The reduction in RA symptoms has 
been observed after a short-term treatment with peficitinib 
(12 weeks)18 and filgotinib (24 weeks).19
In patients with no significant response to MTX or TNF 
inhibitors, the inclusion of ocrelizumab, the monoclonal 
antibody against CD20 protein, as an add-on treatment 
was beneficial as it significantly reduced symptoms of RA. 
Moreover, it proved superior to placebo in all clinical and 
radiographic improvement scales, while the safety profile 
(including serious AEs [SAEs]) was similar between the 
compared groups.13,20
Review of pharmacology, mode of 
action, and pharmacokinetics of 
tofacitinib
Xeljanz® (tafacitinib) (CP-690550) is a JAK-targeted syn-
thetic small-molecule inhibitor modulating cytokines critical 
to the progression of immune and inflammatory responses. 
It preferentially inhibits signaling by receptors associated 
with JAK3 as the main target, with JAK1 and JAK2 also 
being affected at higher concentrations due to a debilitating 
effect on the signaling pathways with nanomolar potency, 
resulting in the inhibition of transmigration of STAT mol-
ecules to the nucleus.21,22 The JAK family, consisting of 
JAK-1, JAK-2, and JAK-3, and tyrosine kinase 2 is essential 
for the signaling pathways of various cytokines and growth 
factors that have been implicated in the pathogenesis of RA, 
which are integral to lymphocyte function and inhibition of 
their signaling and thus modulate the multiple aspects of the 
immune response (eg, IL-2, IL-6, IL-7, IL-12, IL-15, IL-17, 
IL-23, granulocyte-macrophage colony-stimulating factor, 
and interferon [IFN]).23–25
Tofacitinib is a reversible, competitive inhibitor that 
binds to the adenosine triphosphate (ATP)-binding site in 
the catalytic cleft of the kinase domain of JAK and thus 
inhibits the phosphorylation and activation of JAK, thereby 
preventing the activation of STATs and the launching of 
gene transcription. This leads to a decreased cytokine pro-
duction and modulation of the immune response. Tofacitinib 
has a short pharmacokinetic half-life; pharmacokinetic 
profile of tofacitinib in humans is characterized by rapid 
absorption and elimination, with a time to peak concentration 
(T
max
) of ~1 hour and a half-life (t
1/2
) of ~3 hours.25
The clearance mechanisms for tofacitinib in humans 
appear to be both nonrenal (hepatic metabolism, 70%) and 
renal (30%) excretions of the parent drug. The metabolism 
of tofacitinib is primarily mediated by cytochrome P450 
3A4 (CYP3A4; 53%) with a minor contribution from 
CYP2C19 (17%).25
FDA approved Xeljanz® (tofacitinib) (Pfizer, Inc., New 
York, NY, USA) for the therapy of adult patients with 
moderate-to-severe RA in 2012; it was also authorized by 
the European Medicines Agency (EMA) in combination 
with MTX for the treatment of moderate-to-severe active 
RA in adult patients who have responded inadequately to 
or who are not tolerant to one or more DMARDs; in case of 
intolerance or contraindications to MTX, it can be given as 
monotherapy.26
Efficacy studies on tofacitinib in RA, 
including any comparative studies
The efficacy of tofacitinib 5 mg and 10 mg twice a day 
(BID) administered as monotherapy or in combination with 
conventional synthetic DMARDs (mainly MTX) in patients 
with active RA has been shown in Phase III studies24,27–36 in 
a follow-up of up to 24 months and in LTE trials with up to 
105 months.37,38
Tofacitinib was assessed as monotherapy31,33,35 or in com-
bination with conventional synthetic DMARDs24,27,29,30,32,34,36 
in patients with RA who responded poorly to other bio-
logic DMARDs28,29,33 and in MTX-naive patients with 
active RA.35
Tofacitinib demonstrated greater efficacy compared 
with placebo across clinical, functional, and structural 
measures of disease severity24,27–30,32–34,36 as presented in 
Table 1.
As presented in Table 1, the improvement in ACR20 
and ACR50 responses was observed shortly (6 weeks) 
after starting tofacitinib treatment33 and the response levels 
remained significantly higher compared with placebo for up 
to 6 months.24,32,34 The highest ACR20 response (96.3%) was 
found at 12 weeks after the use of tofacitinib at a dose of 5 mg 
BID in a study by Tanaka et al.36 In most studies, the efficacy 
of tofacitinib was dose dependent, with a numerically higher 
response rate observed after a dose of 10 mg BID compared 
with a dose of 5 mg BID.24,27–30,32,34
In patients who had not previously received MTX over 
a 2-year period of treatment, tofacitinib monotherapy at a 
dose of 5 or 10 mg BID was correlated with a significant 
reduction in symptoms of RA, improvement in physical func-
tioning, and delay of structural joint damage, as compared 
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Table 1 Methods and outcomes reported in randomized controlled trials for tofacitinib in RA therapy
References Study groups Inclusion criteriaa Concomitant 
therapy
ACR20b ACR50b
Tofacitinib vs placebo
Burmester 
et al28
Placebo followed by 
tofacitinib 5 mg BID 
(n=66)
Placebo followed by 
tofacitinib 10 mg BID 
(n=66)
Tofacitinib 5 mg BID 
(n=133)
Tofacitinib 10 mg BID 
(n=134)
inadequate response to TNF 
inhibitors
MTX administration
Antimalarials
Corticosteroids
(Month 3)
1. Tofacitinib 5 mg 
vs placebo: 41.7 vs 
24.4% (P=0.0024)
2. Tofacitinib 10 mg 
vs placebo: 48.1 vs 
24.4% (P0.0001)
(Month 3)
1. Tofacitinib 5 mg vs 
placebo: 26.5 vs 8.4% 
(P0.0001)
2. Tofacitinib 10 mg vs 
placebo: 27.8 vs 8.4% 
(P0.0001)
Fleischmann 
et al30
Placebo followed by 
tofacitinib 5 mg BID 
(n=61)
Placebo followed by 
tofacitinib 10 mg BID 
(n=61)
Tofacitinib 5 mg BID 
(n=243)
Tofacitinib 10 mg BID 
(n=245)
inadequate response to at least 
one nonbiologic or biologic 
DMARD
Antimalarials
Corticosteroids
(Month 3)
1. Tofacitinib 5 mg 
vs placebo: 59.8 vs 
26.7% (P0.001)
2. Tofacitinib 10 mg 
vs placebo: 65.7 vs 
26.7% (P0.001)
(Month 3)
1. Tofacitinib 5 mg 
vs placebo: 31.1 vs 
12.5% (P0.001)
2. Tofacitinib 10 mg 
vs placebo: 36.8 vs 
12.5% (P0.001)
van der 
Heijde  
et al24
Placebo followed by 
tofacitinib 5 mg BID 
(n=81)
Placebo followed by 
tofacitinib 10 mg BID 
(n=79)
Tofacitinib 5 mg BID 
(n=321)
Tofacitinib 10 mg BID 
(n=316)
1. Three distinct joint erosions 
on posteroanterior hand and 
wrist
2. Stable doses of MTX were 
required
3. Stable doses of low-dose 
corticosteroids and NSAiDs 
were allowed
(Month 6)
1. Tofacitinib 5 mg 
vs placebo: 51.5 vs 
25.3% (P0.0001)
2. Tofacitinib 10 mg 
vs placebo: 61.8 vs 
25.3% (P0.0001)
(Month 6)
1. Tofacitinib 5 mg vs 
placebo: 32.4 vs 8.4% 
(P0.0001)
2. Tofacitinib 10 mg vs 
placebo: 43.7 vs 8.4% 
(P0.0001)
Kremer  
et al32
Placebo followed by 
tofacitinib 5 mg BID 
(n=79)
Placebo followed by 
tofacitinib 10 mg BID 
(n=80)
Tofacitinib 5 mg BID 
(n=315)
Tofacitinib 10 mg BID 
(n=318)
1. inadequate response to 
treatment with 1 stably 
dosed nonbiologic or biologic 
DMARDs before baseline; 
continue treatment with 
one or more background 
nonbiologic DMARDs at stable 
doses throughout the study
2. MTX administration; 
background, low-dose, oral 
corticosteroid therapy with 
stable dosing (prednisone 
10 mg daily or equivalent) 
was permitted
Background 
DMARDs
MTX
Oral corticosteroids
(Month 6)
1. Tofacitinib 5 mg 
vs placebo: 52.1 vs 
30.8% (P0.001)
2. Tofacitinib 10 mg 
vs placebo: 56.6 vs 
30.8% (P0.001)
Tofacitinib vs placebo; 
difference percentage 
points:
(month 6)
5 mg 28.7%; P0.001
10 mg 30.3%; P0.001
(Month 6)
Tofacitinib vs placebo; 
difference in percentage 
points:
5 mg 22.1%; P0.001
10 mg 24.8%; P0.001
Kremer  
et al33
Placebo (n=65)
Tofacitinib 5 mg BID 
(n=61)
Tofacitinib 15 mg BID 
(n=69)
Tofacitinib 30 mg BID 
(n=69)
1. All patients met the ACR 
1991 revised criteria for 
global functional status in RA 
of class i, ii, or iii
2. inadequate response to, or 
discontinued therapy due to 
unacceptable toxicity from, 
MTX, etanercept, infliximab, 
or adalimumab
3. Patients who discontinue all 
previous DMARD required 
suitable washout
Corticosteroids (week 6)
Tofacitinib 5 mg vs 
placebo: 70.5 vs 29.2% 
(P0.001)
(week 6)
Tofacitinib 5 mg 
increased response 
rates relative to 
placebo (P0.001)
(Continued)
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Table 1 (Continued)
References Study groups Inclusion criteriaa Concomitant 
therapy
ACR20b ACR50b
Kremer  
et al34
Placebo (n=69)
Tofacitinib 1 mg BID 
(n=71)c
Tofacitinib 3 mg BID 
(n=68)
Tofacitinib 5 mg BID 
(n=71)
Tofacitinib 10 mg BID 
(n=75)c
Tofacitinib 15 mg BID 
(n=75)
Tofacitinib 20 mg/day 
(n=80)
1. Patients must have been 
receiving oral or parenteral 
MTX continuously  
for 4 months
2. All other biologic or 
nonbiologic DMARDs and 
immunosuppressive therapy 
were discontinued 4 weeks 
prior to the study
Corticosteroids (week 12)
1. Tofacitinib 5 mg 
vs placebo: 50.7 vs 
33.3% (P0.05)
2. Tofacitinib 10 mg 
vs placebo: 58.1 vs 
33.3% (P0.05)
(week 24)
1. Tofacitinib 5 mg 
(29.0%) was higher 
vs placebo (P0.05)
2. Tofacitinib 10 mg 
(22.6%) was 
significantly higher 
vs placebo (P0.05)
(week 12)
Tofacitinib 5 mg 
increased response 
rates relative to 
placebo (P0.05)
Tanaka  
et al36
Placebo (n=28)
Tofacitinib 1 mg BID 
(n=28)c
Tofacitinib 3 mg BID 
(n=27)c
Tofacitinib 5 mg BID 
(n=27)c
Tofacitinib 10 mg BID
(n=26)c
1. inadequate clinical response 
to MTX; all patients were 
required to remain on stable 
background MTX 6 mg/week
2. All other traditional and 
biologic DMARDs and 
immunosuppressive therapy 
were discontinued at least 
4 weeks prior to the study
Low-dose 
corticosteroids
(week 12)
1. Tofacitinib 5 mg 
vs placebo: 96.3 vs 
14.3% (P0.0001)
2. Tofacitinib 10 mg 
vs placebo: 80.8 vs 
14.3% (P0.0001)
(week 12)
Tofacitinib treatment 
had significantly greater 
effect vs placebo:
5 mg (P0.0001), 
10 mg (P0.001)
Tofacitinib vs MTX
Lee et al35 Tofacitinib 5 mg BID 
(n=373)
Tofacitinib 10 mg BID 
(n=397)
MTX (n=186)
3 distinct joint erosions 
detected on hand and wrist or 
foot radiographs or a positive 
test for igM rheumatoid 
factor or antibodies to cyclic 
citrullinated peptide
(Month 24)
Tofacitinib 5 mg: 
64.2%
Tofacitinib 10 mg: 
64.2%
MTX: 42.4%
Tofacitinib 5 and 
10 mg for the 
comparison with MTX 
(P0.001)
(Month 24)
Tofacitinib 5 mg: 49.3%
Tofacitinib 10 mg: 
49.2%
MTX: 28.3%
Tofacitinib 5 and 10 mg 
for the comparison 
with MTX (P0.001)
Tofacitinib or adalimumab vs placebo
Fleischmann 
et al29
Placebo (n=59)
Tofacitinib 1 mg BID 
(n=54)
Tofacitinib 3 mg BID 
(n=51)
Tofacitinib 5 mg BID 
(n= 49)
Tofacitinib 10 mg BID 
(n=61)
Tofacitinib 15 mg BID 
(n=57)
Adalimumab 40 mg 
qow (n=53)
Failure of at least one DMARD 
due to lack of efficacy or 
toxicity and washout of all 
DMARDs except antimalarial 
agents at stable doses
Antimalarials
Corticosteroids
(week 24)
1. Tofacitinib 5 mg 
vs placebo: 51.0 vs 
25.4% (P0.05)
2. Tofacitinib 10 mg 
vs placebo: 65.6 vs 
25.4% (P0.0001)
(week 24)
1. Tofacitinib 5 mg 
vs placebo: 34.7 vs 
10.2% (P0.05)
2. Tofacitinib 10 mg 
vs placebo: 44.3 vs 
10.2% (P0.0001)
van 
vollenhoven 
et al27
Placebo followed by 
tofacitinib 5 mg BID 
(n=56)
Placebo followed by 
tofacitinib 10 mg BID 
(n=52)
Tofacitinib 5 mg BID 
(n=204)
Patients were receiving 
7.5–25 mg of MTX weekly and 
had an incomplete response
Corticosteroids (Month 6)
1. Tofacitinib 5 mg 
vs placebo: 51.5 vs 
28.3% (P0.0001)
2. Tofacitinib 10 mg 
vs placebo: 52.6 vs 
28.3% (P0.001)
(Month 6)
Significantly greater 
responses were 
seen with the active 
treatments than with 
placebo (P0.05)
(Continued)
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Table 1 (Continued)
References Study groups Inclusion criteriaa Concomitant 
therapy
ACR20b ACR50b
Tofacitinib 10 mg BID 
(n=201)
Adalimumab 40 mg 
q2w (n=204)
Tofacitinib monotherapy vs tofacitinib and MTX vs adalimumab and MTX
Fleischmann 
et al31
Tofacitinib 5 mg 
BID monotherapy 
(n=384)
Tofacitinib 5 mg BID 
and MTX (n=376)
Adalimumab 40 mg 
qow and MTX 
(n=386)
1. Classes i–iii functional 
capacity as classified by the 
ACR 1991 revised criteria for 
RA
2. inadequate responders to 
MTX treatment
3. Patients were required to 
discontinue all conventional 
synthetic DMARDs other 
than MTX but could continue 
to receive stable nonsteroidal 
anti-inflammatory drugs, 
analgesics, or oral 
corticosteroids or a 
combination
Corticosteroid use 
at baseline
(Month 12)
1. Tofacitinib 
monotherapy: 39%
2. Tofacitinib and MTX: 
48%
3. Adalimumab and 
MTX: 46%
Notes: ACR20 indicates that symptoms have improved 20% from baseline. ACR50 indicates that symptoms have improved 50% from baseline. ainclusion criteria in all studies 
were as follows: at least 18 years old and active moderate-to-severe RA based on the ACR 1987 revised criteria. bThe results were presented only for registered doses of 
tofacitinib (5 mg and 10 mg BID). cRandomized and treated patients.
Abbreviations: ACR, American College of Rheumatology; BID, twice a day; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal 
anti-inflammatory drugs; q2w, every 2 weeks; qow, once every other week; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
with MTX.35 Another study reported high efficacy of tofaci-
tinib in patients who had shown an inadequate response to 
DMARDs.30
In treatment-refractory patients, of whom one-third had 
previously been treated with two or more TNF inhibitors, 
tofacitinib at doses of 5 and 10 mg BID showed rapid, sig-
nificant, and clinically meaningful improvements compared 
with placebo. All primary and secondary outcomes improved 
with both doses vs placebo at 3 months.28
With regard to secondary endpoints related to disease 
activity, clinically meaningful and statistically significant 
reductions from baseline in disease activity score (DAS28)
erythrocyte sedimentation rate (ESR) scores (indicating 
decreased disease activity) were observed in the tofacitinib 
group at 3 months, as compared with placebo.30 Patients 
receiving tofacitinib also demonstrated clinically meaningful 
improvements in the levels of fatigue and pain.24,30,32 
Significant differences between the tofacitinib and placebo 
groups in both ACR and HAQ-DI responses were reported 
at 2 weeks.30 Tofacitinib in combination with nonbiologic 
DMARDs, primarily MTX, was superior to placebo in terms 
of the rates of ACR20 response and DAS28 (ESR)-defined 
remission and in improving HAQ-DI scores in patients with 
active RA.24,28,32,36
The results of a 6-week Phase IIa trial showed that 
tofacitinib administered at a dose of 5 mg BID improved the 
ACR20, ACR50, and ACR70 response rates in the treatment 
of active RA. In many patients, these improvements were 
already seen at 1 week.33
In a Phase IIb study, tofacitinib was investigated for 
the treatment of patients with active RA who had shown 
inadequate response to MTX monotherapy. Over 24 weeks, 
tofacitinib at doses 3 mg BID was effective in terms of 
improving the ACR response rates. The efficacy was already 
established at 2 weeks and was still observed at 24 weeks.34 
Tofacitinib at doses of 5 and 10 mg BID showed rapid action, 
and a clinically significant change in ACR20 and ACR50 
response rates from baseline was reported at 1 week, followed 
by an improvement in the quality of life scores.36
The efficacy of the 5 or 10 mg tofacitinib dose over the 
12-month study period was significantly superior to pla-
cebo with respect to all clinical outcomes. The results were 
similar to those of adalimumab at a dose of 40 mg every 
2 weeks.27,29
The ACR20 response rate at 12 weeks reached 88.6% 
and was maintained throughout the LTE study (up to 
264 weeks). An increase in the ACR20 response rate was 
notable in patients who did not show adequate response to 
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
9.
15
6.
73
.3
9 
on
 2
6-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
21
Tofacitinib in rheumatoid arthritis
tofacitinib at a dose of 5 mg BID when the dose increased 
to 10 mg BID. The ACR50 and ACR70 response rates were 
65.5 and 42.5%, respectively, at 12 weeks, and these results 
were also maintained throughout the study.38 These findings 
were confirmed by another LTE study, in which the ACR20, 
ACR50, and ACR70 response rates were maintained over 
the 48-month period.37
The Oral Rheumatoid Arthritis Trial (ORAL) Strategy 
aimed to assess the comparative efficacy of tofacitinib mono-
therapy, tofacitinib with MTX, and adalimumab with MTX 
for the treatment of RA in patients with a previous inadequate 
response to MTX.31 A combination therapy of tofacitinib and 
MTX was noninferior to a combination of adalimumab and 
MTX, while tofacitinib monotherapy was not shown to be 
noninferior to either combination.31
While direct comparisons for biologics in RA are quite 
rarely an option for clinical trials and no robust data are 
available, indirect comparisons (NMAs) could provide the 
most relevant and comprehensive data for the relative effi-
cacy assessment. An NMA by Vieira et al12 revealed that 
tofacitinib at a dose of 5 mg BID combined with MTX was 
similar in terms of the relative risk (RR) of ACR20, ACR50, 
and ACR70 responses to abatacept, golimumab, rituximab, 
and tocilizumab combined with conventional DMARDs 
during the follow-up period of 12 and 24 weeks. The results 
of the NMA suggest that tofacitinib at a dose of 5 mg BID 
was more effective than placebo and comparable with the 
biologics in terms of efficacy, as measured by HAQ-DI 
improvement at 12 weeks.12
The above findings were confirmed by another NMA, 
which aimed to assess the efficacy of tofacitinib at a dose of 
5 and 10 mg used as either monotherapy or combined with 
MTX or DMARDs, in comparison with biologic therapies 
at 24 weeks. The biologics included abatacept, adalimumab, 
anakinra, certolizumab pegol, etanercept, golimumab, inflix-
imab, tocilizumab, and baricitinib.39
Tofacitinib 5 mg was comparable to the other monothera-
pies at 24 weeks in terms of ACR20 and ACR70 response 
rates, while tofacitinib 10 mg had more effective ACR20, 
ACR50, and ACR70 response rates compared to placebo 
and was comparable to other monotherapies. Tofacitinib 
5 mg demonstrated both greater efficacy than placebo and 
comparability to other monotherapies for ACR50 responses. 
For all ACR20, ACR50, and ACR70 responses at 24 weeks, 
tofacitinib 5 or 10 mg combined with DMARDs was more 
effective than placebo accompanied by DMARDs or MTX 
and showed comparable responses to other combination 
therapies.39
In addition, for the ACR70 responses, tofacitinib 5 and 
10 mg were more effective than certolizumab 400 mg, 
all combined with DMARDs or MTX. Tofacitinib 10 mg 
revealed much higher efficacy in ACR20 response than etan-
ercept 50 mg, abatacept 10 mg/kg, and infliximab 3 mg/kg; all 
combined with DMARDs. The ACR50 response at 24 weeks 
indicated significantly higher efficacy rates of tofacitinib 
5 and 10 mg compared to baricitinib (all administered with 
concomitant therapies), while tofacitinib 10 mg provided 
significantly higher ACR50 response compared to etanercept 
50 mg, abatacept 125 mg, and infliximab 3 mg/kg; all admin-
istered with MTX or DMARDs. For the ACR70 response 
at 24 weeks, preponderance of tofacitinib over adalimumab 
40 mg and abatacept 10 mg/kg combination treatments was 
revealed. In addition, tofacitinib 10 mg was more efficacious 
than etanercept 25 mg, etanercept 50 mg, infliximab 3 mg/kg, 
and baricitinib 2 mg; all administered with DMARDs.39
Comparative safety and tolerability 
of tofacitinib
Tofacitinib efficacy in RA is related to its strong immunosup-
pressive action reflected by inhibition of JAK-STAT activa-
tion, decrease in cytokine production, and modulation of 
lymphocyte proliferation;12 thus, a majority of AEs are related 
to reduced immunity status. The most common reported AEs 
in clinical trials by system organ class included: nasopharyn-
gitis,28,29,31,32,34,36,37 upper respiratory tract infections,29–32,34,37 
urinary tract infections,28,29,31,33,34 and bronchitis.28,29
Other most frequently revealed AEs were as follows: 
gastrointestinal disorders24,33–35 such as diarrhea28–30 and 
nausea,29,31,33,34 nervous system disorders33 including 
headache28–30,33,36 and dizziness,29 and abnormalities in 
laboratory parameters.24,30,31,33,34,36 Although the majority of 
AEs across all dosages of tofacitinib were mild to moderate 
in severity,29,31,34,36 some of them were serious, such as 
opportunistic infections (herpes zoster, tuberculosis, and 
cytomegalovirus),24,30,32,35 malignancies,31,33,35 cardiovas-
cular (CV) events,29,30 abnormalities in clinical laboratory 
parameters,29,30 and gastrointestinal perforations.29
In the short-term observation period (6 weeks), the inci-
dence of any AEs was 59% at both tofacitinib 5 mg BID and 
in the placebo groups, with the infection rate of 24.6% in 
tofacitinib 5 mg BID vs 26.2% in the placebo group.33
Between 0 and 3 months’ follow-up, treatment-emergent 
AEs (TEAEs) were reported with similar frequency in patients 
treated with tofacitinib at 5 mg BID (48.9%), tofacitinib at 
10 mg BID (54.1%), and placebo (45.6%).24 In another study,36 
five cases of SAEs were reported across all tofacitinib treated 
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groups. SAEs occurred in numerically lower incidence in the 
tofacitinib 5 and 10 mg BID group (1.5%) than in the placebo 
group (4.5%), and no serious infection events were reported. 
Discontinuations rate due to TEAEs was similar in the tofaci-
tinib group (5.2%) to the placebo group (5.3%).28
Between 3 and 6 months, 41.9% of the patients across 
all tofacitinib groups experienced TEAEs and 4% of the 
patients suffered from SAEs (serious infections).28 Similar 
results were reported at 6 months in a follow-up study by 
Fleischmann et al.29 Across all tofacitinib-treatment arms, 
53.7% of the patients experienced TEAEs, while SAEs 
occurred in 2.9% of the patients treated with tofacitinib 
compared with 5.9% of the patients receiving placebo. The 
rate of infections with tofacitinib at a dose of 5 and 10 mg 
BID was 34.7 and 34.4%, respectively, compared with 17.6% 
of the patients in the placebo group. The most common sig-
nificant infections in the tofacitinib groups were urinary tract 
infections (3.7%), pneumonia (1.5%), and sinusitis (0.7%).29 
During the same follow-up period in a study by Kremer et al,34 
21 patients (4.1%) experienced SAEs, including five cases 
of serious infections. An increased rate of serious infections 
with tofacitinib as compared with placebo was reported in a 
study by Fleischmann et al.30 Serious infections were reported 
in six patients treated with tofacitinib and included cellulitis, 
liver abscess, bronchitis, tuberculous pleural effusion, and 
pyelonephritis. In the placebo group, there were two inci-
dences of cellulitis in one patient.30
During the 12-month follow-up, the incidence rates (IRs) 
of AEs calculated per 100 patient-years (py) of exposure 
were numerically lower in patients receiving tofacitinib 
5 and 10 mg BID (IR =6.9 and 7.3, respectively) as compared 
with placebo (IR =10.9), with a similar tendency for the IR 
of SAEs (IR =171.9, 175.7, and 342.3 for patients receiving 
tofacitinib 5 and 10 mg and placebo, respectively).32 The IRs 
of serious infections per 100 py at 12 months in a study by 
van der Heijde et al24 were 4.17, 2.32, and 3.68 for the 5 and 
10 mg doses and placebo, respectively. In another study, 
the IR of serious infections during a 12-month follow-up 
was numerically higher in patients receiving the 5 mg dose 
(3.4%) and the 10 mg dose (4%) than in the adalimumab 
group (1.5%).27 Finally, in a study by Fleischmann et al,31 
combined MTX and tofacitinib monotherapy increased the 
incidence of AEs and TEAEs from 59% to 61% and from 
26% to 30%, respectively, over 12 months.
A 24-month follow-up in a study by Lee et al35 revealed 
numerically similar data for the safety of tofacitinib and MTX 
treatment. The incidence of AEs was 79.6, 84.1, and 79.0%; 
the incidence rate of SAEs – 10.7, 10.8, and 11.8%, and of 
serious infections – was 3.0, 2.0, and 2.7% for tofacitinib 
5 and 10 mg BID and MTX, respectively.35
An integrated analysis of Phase I–III clinical trials and 
LTE studies with tofacitinib in patients with RA showed 
that the IR of AEs, SAEs, and withdrawals due to AEs was 
numerically similar for both registered doses of tofacitinib 
(5 and 10 mg BID), regardless of whether the dose was aver-
age or constant. Infections, CV events, and malignancies 
were the most common causes of death.40
Pooled data from five Phase III studies suggested that 
younger patients (65 years) had a lower risk of SEAs, seri-
ous infections, and withdrawal due to AEs than older patients 
(65 years). However, this could be related to comorbidities, 
which occur more often in older patients, and the results 
should therefore be interpreted with caution.41
Safety of tofacitinib relative to 
other biologic therapies
Due to the absence of direct comparisons of tofacitinib with 
biologic treatments in patients with RA, the only available 
safety results were based on NMA; findings indicated a 
comparable safety profile of tofacitinib and other biologic 
DMARDs used in RA.12,39 In patients treated with tofacitinib 
5 mg BID, who had an inadequate response to TNF inhibitors, 
the risk of AEs, SAEs, and any discontinuations due to AEs 
was similar to other biologic DMARDs including abatacept, 
golimumab, tocilizumab, and rituximab; moreover, no sig-
nificant differences were revealed compared to placebo. The 
rate of withdrawals due to limited efficacy was significantly 
reduced during tofacitinib treatment compared to abatacept, 
golimumab, tocilizumab, and placebo.12
The results of another NMA showed that tofacitinib mono-
therapy (5 or 10 mg BID) was associated with significantly 
lower risk of discontinuation due to AEs in patients with 
moderate or severe RA in relation to adalimumab 40 mg, 
every 2 weeks, and similar to other therapies (tocilizumab, 
adalimumab 40 mg once a week, etanercept, and certolizumab) 
and placebo. The rate of withdrawals due to AEs was higher 
during combination therapy of tofacitinib (5 or 10 mg BID) 
and DMARDs in comparison to placebo or abatacept added to 
DMARDs; for the remaining combination therapies, the rate was 
similar. Tofacitinib added to MTX did not have a significantly 
higher rate of discontinuation due to AEs compared to other bio-
logic treatments or placebo, both in combination with MTX.39
Opportunistic infections
Clinical evidence suggests that tofacitinib treatment is asso-
ciated with an increased risk of infections. Considering its 
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mechanism of action affecting the immune system and the 
increased baseline risk of herpes zoster among patients with 
RA, an increased risk of opportunistic infections is quite an 
important issue.40,42,43 As expected, the cases of opportunis-
tic infections were reported in main randomized controlled 
trials (RCT); the summary of these events is presented in 
Table 2.
In short-term therapy, no opportunistic infections were 
reported, but between 6 and 12 months, in tofacitinib 5 mg 
and 10 mg therapies cases appeared of opportunistic infec-
tions such as herpes zoster,24,31,32,34 tuberculosis,24,27,30–32 
cryptococcal pneumonia,32 candidiasis,24 cytomegelovirus,24 
and varicella zoster.31 At 24 months’ observation, the rate of 
herpes zoster infection was 4.5%.35
A review of Phase II, Phase III, and LTE studies from 
a tofacitinib program in RA showed an increase in the risk 
of opportunistic infections, which was numerically higher 
in patients receiving a dose of 10 mg BID than that of 5 mg 
BID.44 Another review of RCT and LTE studies revealed 
increased IRs of herpes zoster (IR =4.4/100 py) in patients 
treated with tofacitinib, particularly among Asian patients.45 
The authors reported that complicated cases of herpes zoster 
among tofacitinib-treated patients were rare45 and visceral 
disease was not reported. The rates of herpes zoster were 
similar between the low- and high-dosage tofacitinib groups; 
although during the first few months after initiating the 
therapy, a higher risk was observed in the group receiving the 
10 mg dose. Data suggest that preventive strategies for herpes 
zoster should be developed for patients with RA, given the 
high rate of morbidity observed regardless of RA therapy.45 
The results from a meta-analysis of tofacitinib trials in RA 
also confirmed an increased risk of herpes virus infection 
(IR =3.87).46 As compared with other biologic DMARDs, the 
absolute rate differences for herpes zoster during tofacitinib 
treatment were approximately doubled per 100 py.46
The safety analysis of exposure to tofacitinib among 6,194 
adult patients, with RA up to 8.5 years, from two Phase I, 
nine Phase II, six Phase III, and two LTE studies revealed 
that the rate of AEs was generally stable over time. The IR 
of serious infections was 2.7/100 py, and the IR of herpes 
Table 2 Opportunistic infections reported in randomized controlled trials for tofacitinib in RA, regarding follow-up periods
References Follow-up period Opportunistic infection/tuberculosis/herpes zoster (% or number of cases)
Kremer et al33 6 weeks No opportunistic infections
Tanaka et al36 3 months No opportunistic infections
Fleischmann et al30 6 months One case (0.4%)a of serious tuberculous pleural effusion (tofacitinib 10 mg BID)
Kremer et al34 6 months 1.4% of patients with herpes zoster infection (tofacitinib 1, 3, 5, 10, and 15 mg BID)
Burmester et al28
Fleischmann et al29
6 months No opportunistic infections
Kremer et al32 0–6 months Four cases (0.5%)a of opportunistic infections (tofacitinib 5 and 10 mg BID) related to treatment: 
disseminated herpes zoster, cryptococcal pneumonia, and two cases of pulmonary tuberculosis
6–12 months Two cases (0.5%)a of pulmonary tuberculosis, one case of peritonitis and cryptococcal pneumonia 
(tofacitinib 10 mg BID)
van der Heijde et al24 12 months Seven cases (1%)a of opportunistic infections: three serious (pneumonia and cytomegalovirus 
infections) and four nonserious (lymph node tuberculosis or candidiasis) (tofacitinib 5 and 10 mg BID)
van vollenhoven et al27 12 months Two cases (1%)a of pulmonary tuberculosis (tofacitinib 10 mg BID); cases of herpes zosterb 
(tofacitinib 5 and 10 mg BID)
Fleischmann et al31 12 months 1% of patients with opportunistic infections (tofacitinib 5 mg BID) and 2% of patients with 
opportunistic infections (tofacitinib 5 mg BID + MTX)
Documented herpes zoster: 1% of patients in the tofacitinib 5 mg BID and 2% of patients in 
tofacitinib 5 mg BID + MTX
1% of patients with mild cases of herpes zoster after vaccination; one case (0.3%)a of serious varicella 
zoster event (tofacitinib 5 mg BID); one case (0.3%)a of serious herpes zoster (tofacitinib 5 mg  
BID + MTX)
One case (0.3%)a of tuberculosis in tofacitinib 5 mg BID and one case (0.3%)a in tofacitinib 5 mg  
BID + MTX
Lee et al35 24 months 3.5% of patients with herpes zoster infection in tofacitinib 5 mg BID and 4.5% in patients in tofacitinib 
10 mg BID
One case (0.3%)a of serious herpes zoster infection (tofacitinib 5 mg BID), two cases (0.5%)a of 
serious herpes zoster infection (herpes zoster and disseminated herpes zoster), and one case (0.3%)a 
of serious bone tuberculosis (tofacitinib 10 mg BID)
Notes: aPercentage was calculated according to the information provided in the reference publication. bNo precise information on the number of cases or percentage of 
affected patients in the reference publication.
Abbreviations: BID, twice a day; MTX, methotrexate; RA, rheumatoid arthritis.
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zoster was 3.9/100 py. Moreover, the analysis by 6-month 
intervals did not reveal any notable increase in the risk of 
serious infections and herpes zoster with longer exposure to 
tofacitinib. The rates of complicated herpes zoster or serious 
herpes zoster infections were low and comparable with those 
of multidermatomal and ophthalmic herpes zoster reported 
with other DMARDs.40
A common opportunistic infection revealed in RCT trials 
(Table 2) was tuberculosis, although it was quite rare in the 
regions of low prevalence. This suggests that latent infec-
tions are incited by tofacitinib treatment.40,44 Patients with 
RA show a generally higher incidence of tuberculosis than 
the general population or patients receiving TNF inhibitors. 
However, a higher risk of tuberculosis infection after treat-
ment with tofacitinib was shown to be within the range for 
biologic DMARDs.40
CV AEs
According to clinical studies, patients with RA have an 
increased risk of CV disease and CV-related death compared 
with the general population.47,48
One death attributed to a cerebrovascular accident was 
reported in a patient receiving tofacitinib at a dose of 15 mg 
BID, but no CV events were reported for tofacitinib at the 
doses of 5 mg and 10 mg during a 6-month follow-up. In the 
same study, hypertension developed in 2% of the patients 
receiving tofacitinib at a dose of 5 mg BID and 4.9% of those 
receiving with tofacitinib at a dose of 10 mg BID compared 
with 2.9% of the patients receiving placebo. However, 
none of these cases were classified as severe.29 In a study by 
Fleischmann et al,30 two patients in the 10 mg group devel-
oped congestive heart failure within 6 months of therapy.
During a 12-month follow-up, nonfatal major adverse 
events were not revealed in the groups receiving tofacitinib 
or a combination of tofacitinib and MTX groups, while there 
were two events (1%) in the group receiving adalimumab and 
MTX.31 During the same period in a study by van der Heijde 
et al,24 no patient had congestive heart failure; however, six 
patients treated with tofacitinib experienced six non-fatal CV 
events: three of them were classified as CV events (carotid 
artery stenosis, angina pectoris, and coronary artery disease) 
and the others as cerebrovascular events (lacunar infarction 
and cerebral infarction).
In another study, the following three CV events occurred 
during 12 months of tofacitinib therapy: transient ischemic 
attack, cerebrovascular accident (both at the 5 mg dose), and 
congestive heart failure (10 mg).32
CV safety findings in patients with RA were assessed 
in a pooled analysis, including 3,942 py of follow-up in 
Phase III studies and 8,699 py of follow-up in LTE studies 
on tofacitinib. Treatment with tofacitinib (5 or 10 mg BID) 
was associated with a low rate of CV events, despite short- 
and long-term increases in traditional levels. The rates of 
CV events with tofacitinib were generally similar to those 
observed for placebo, adalimumab, and MTX. Furthermore, 
the rates of CV events did not increase with longer treatment 
duration. Blood pressure was generally stable over time, 
and in Phase III studies, the number of hypertension-related 
AEs was low during tofacitinib treatment. These data were 
consistent with previously reported rates of CV events among 
patients with RA, including those treated with TNF inhibi-
tors; however, analyses with longer follow-up are needed to 
confirm these findings.49
Malignancies
Chronic inflammation and autoimmune diseases such as RA, 
as well as clinical use of immunosuppressive drugs, are poten-
tially correlated with an increased risk of malignancy.30,50
Malignancies were reported in some RCTs, and the 
following six cases of cancer in a 6-month follow-up were 
revealed: non-Hodgkin’s lymphoma, chronic lymphocytic 
leukemia (tofacitinib 5 mg), prostate cancer, Burkitt’s B-cell 
lymphoma, colon cancer (tofacitinib 10 mg), and only gastric 
cancer in the MTX group.35 A 12-month follow-up revealed 
cases of salivary gland neoplasm, benign hair follicle tumor, 
metastatic renal-cell carcinoma, and non-small-cell lung 
cancer diagnosed in the group receiving the 5 mg dose of 
tofacitinib and cholesteatoma, cervix carcinoma, and benign 
ovarian germ-cell teratoma in the group receiving the 10 mg 
dose of tofacitinib.27 However, in another study of 12 months’ 
duration, the number of malignancies was lower: one case 
(1%) was reported in the tofacitinib monotherapy group, 
while two other patients (1%) developed nonmelanoma 
skin cancer (NMSC).31 In another study, nine patients were 
diagnosed with carcinomas: basal cell carcinoma (four cases), 
stomach adenocarcinoma (two cases), bone squamous cell 
carcinoma (one case), non-Hodgkin’s lymphoma (one case), 
and breast mucinous adenocarcinoma (one case) during 
12 months of the 24 months’ follow-up. In addition, one 
patient in the tofacitinib-treated group (10 mg) had uncon-
firmed diagnosis of cervical squamous cell carcinoma.24
No cases of malignancies were revealed in other RCT 
studies;28,29,32–34,36 however, RCTs are inadequate to detect and 
evaluate rare events, such as malignancies, in comparison 
with LTE studies, which offer better chances to evaluate 
rare events.51
A meta-analysis and NMA of long-term RCTs 
(12 months) showed that the risk of all malignancies, solid 
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malignancies, and hematological malignancies associated 
with the use of biologic DMARDs and tofacitinib was not 
increased compared with placebo or conventional synthetic 
DMARDs.51 A meta-analysis of RCT trials revealed a Peto 
odds ratio (OR) of overall malignancies not significantly 
higher compared with placebo (Peto OR =2.08; 95% CI: 
0.50, 8.59), while the analysis of LTE studies demonstrated 
an IR of 1.78/100 py (95% CI: 1.50, 2.07) for tofacitinib 
treatment.51
Aggregated data from six Phase II, six Phase III, and two 
LTE studies involving tofacitinib (5 or 10 mg BID) revealed 
107 cases of malignancy among 5,671 patients treated with 
tofacitinib (with the exception of NMSC). The most common 
malignancies were lung cancer (24 cases), breast cancer 
(19 cases), lymphoma (10 cases), and gastric cancer (six 
cases). The overall rates and types of malignancies remained 
stable over time irrespective of increasing the exposure to 
tofacitinib. Standardized IR for all malignancies (except 
NMSC) as well as lung cancer, breast cancer, lymphoma, 
and NMSC were within the expected range for patients with 
moderate or severe RA.50
Clinical trials and LTE studies involving tofacitinib-
treated patients with RA reported a risk of NMSC of 1.16%, 
with the overall IR of 0.53/100 py (95% CI: 0.41, 0.67). 
The rates of NMSC in RCT studies were similar between 
patients receiving tofacitinib at a dose of 5 and 10 mg BID, 
while LTE studies suggested the dose-dependent risk of 
cancer.50 These findings were confirmed by a meta-analysis 
of 18 studies (two Phase I, eight Phase II, six Phase III, 
and two LTE studies), which revealed 83 (1.36%) cases 
of NMSC in a group of 6,092 tofacitinib-treated patients 
with RA. The risk of NMSC was generally small and 
stable (IR =0.55/100 py) during the 84-month follow-up.52 
A numerically higher IR of NMSC in LTE studies was 
observed during therapy with the 10 mg dose in compari-
son with the 5 mg dose. However, further LTE studies are 
necessary to confirm these data.52
White blood cell parameters
Most clinical trials revealed a general tendency for a reduction 
in neutrophil29,34,35 and lymphocyte counts,35 but the distur-
bances usually stabilized during therapy.53 The mechanism by 
which tofacitinib decreases the circulating neutrophil count 
may be associated with the inhibition of JAK-dependent 
IL-6 signaling, which is involved in neutrophil activation, 
or with more general anti-inflammatory effects.53 In Phase II 
studies of tofacitinib in RA, the reduced neutrophil count was 
accompanied by a decrease in hemoglobin levels, which in 
some cases was clinically significant (2 g/dL).54
A significant decrease in neutrophil and lymphocyte 
counts was observed in a group receiving tofacitinib at a dose 
of 10 mg compared to the MTX group during 24 months’ 
follow-up.35 The incidence of confirmed mild neutropenia 
was 9.1% with tofacitinib at a dose of 5 mg BID and 6.5% 
with tofacitinib at a dose of 10 mg BID, but neither was clas-
sified as severe or life threatening.29 Lower neutrophil count 
was observed with tofacitinib treatment in a dose-dependent 
manner in comparison with placebo at 12 months.34 In a 
number of studies, a decrease in neutrophil count was usually 
slight and none of the patients showed a potentially life-
threatening reduction in absolute neutrophil count (febrile 
neutropenia).24,28,30,32,34
LTE studies reported a decreased mean neutrophil count 
during tofacitinib treatment (Table 3). The mean lymphocyte 
count increased slightly during the first 3 months of treatment 
with either dose of tofacitinib, and after that time, progres-
sively decreased in Phase III studies. A further slow decrease 
was revealed up to month 48 in LTE studies with both doses 
of tofacitinib and then it stabilized.53
Cholesterol levels
During Phase II studies, an increase in low-density lipo-
protein (LDL) cholesterol and high-density lipoprotein 
(HDL) cholesterol levels was observed in patients with 
active RA receiving treatment with tofacitinib.29,32,34,36,55 In 
Table 3 Clinical laboratory results during tofacitinib treatment in RA
Parameter Observation period
0–3 months 3–24 months 24 months  
(LTE studies)
Neutrophil count Decrease53 Slow decrease53 Stabilization53
Lymphocyte count increase53 Slow decrease53 Stabilization53
Hemoglobin level increase53 Slow increase up to 12 months; 
then stabilization53
No clear 
tendency53
LDL level increase24,30,32,33 Increase or stabilization24,29,30,35 Stabilization38
HDL level increase32,33 Increase or stabilization29,35 No data available
Serum creatine level increase24,32 Slow increase24,34,35 Stabilization38
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; LTe, long-term extension studies; RA, rheumatoid arthritis.
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several studies, a dose-dependent elevation of LDL,30,32,33,35,36 
HDL,32,33,35,36 and total cholesterol29,32,33,36 was observed. 
Generally, an increase in lipid levels occurred shortly after 
starting tofacitinib treatment (week 2), reached the highest 
value at 6–8 weeks, and then appeared to plateau, in a study 
by Kremer et al,34 while plateau was observed between 4 and 
12 weeks in a study by Tanaka et al,36 and between 3 and 
12 months in a study by Kremer et al32 (Table 3).
A study by Fleischmann et al29 reported increased levels 
of total, HDL, and LDL cholesterol in all tofacitinib-treated 
groups (41.2% [5 mg dose] and 56.4% [10 mg dose]) than 
in the placebo group (24.0%). During a 3-month follow-up 
in a study by Fleischmann et al,30 the mean LDL cholesterol 
level increased by 3.5% in the placebo group compared 
with 13.6% in the group receiving the 5 mg dose and 19.1% 
in the group receiving the 10 mg dose. In another study, an 
increase in HDL and LDL cholesterol levels was 10% in the 
tofacitinib groups and 7% in the placebo group.28 During 
the 24-month follow-up, the mean LDL cholesterol levels 
increased by 18.6, 21.6, and 3.9% in the tofacitinib 5 and 
10 mg and MTX groups, respectively, while HDL choles-
terol levels increased by 16.8, 17.4, and 7.0%, respectively.35 
A meta-analysis of clinical trials on tofacitinib revealed the 
RR of hypercholesterolemia to be 1.70 (95% CI: 1.10, 2.63) 
and to be dose dependent.56
Hemoglobin
Some decrease in hemoglobin level during tofacitinib treat-
ment was revealed in reference clinical trials.27,28,34 Mean 
changes from baseline in the hemoglobin level were low 
across all tofacitinib treatment groups at the 6 months’ 
period.29 In the follow-up period of 3 months, the rate of 
patients with decreased hemoglobin was no higher in the 
tofacitinib treatment groups (7.8% for 5 mg BID and 12.9% 
for 10 mg BID) than in the placebo group (10.2%) and most 
cases of decreased hemoglobin were mild to moderate in 
severity28 and did not impose treatment discontinuations29,34 
or cause anemia34 except for in one study reporting 4.2% 
of cases of anemia in the tofacitinib 10 mg BID group.29 
Changes were seen during months 0–3 of active treatment 
and stabilized in most cases in 6 months.28 Only one patient 
in the tofacitinib 10 mg group experienced potentially life-
threatening hemoglobin decrease in the follow-up period of 
12 months.27
Results of six RCT studies of 6–24 months duration, col-
lected in a pooled analysis, revealed low incidence of clini-
cally meaningful reductions in hemoglobin and incidence of 
anemia for tofacitinib treatment, similar to placebo or MTX. 
Reductions in fatigue and improvements in vitality demon-
strated during tofacitinib treatment were largely independent 
of hemoglobin changes. Generally a numerically higher 
hemoglobin level was reported in tofacitinib 5 mg (0.47 g/
dL) and 10 mg BID (0.28 g/dL) up to 24 months compared to 
placebo group (-0.01 g/dL) in 6 months follow-up. . Results 
of LTE studies showed that changes in hemoglobin were 
generally stable up to 66 months (Table 3), with similar per-
centages of patients with decreased level in both tofacitinib 
5 and 10 mg BID groups.53
Creatine kinase
Recent evidence showed an increase in serum creatine level 
after initiation of tofacitinib treatment.24,29,31–36 Significant 
but not clinically meaningful increases in creatine level in 
tofacitinib groups were reported in a study,36 while elevation 
of creatine level was a cause of treatment discontinuation 
in four patients during 12 months of tofacitinib therapy.32 
Persistent increase in serum creatine level was reported in 
six patients.29 A total of 51 patients had an elevation of serum 
creatine not fully resolved by the end of the study,33 but in 
most cases, the level returned to within 10% of their base-
line. The elevation of serum creatine 50% from baseline 
occurred during a 12 months’ period in 1% of patients with 
RA treated with tofacitinib (5 and 10 mg); however, none 
of them experienced renal failure.24 In case of three patients 
(two in the tofacitinib 5 mg and one in the 10 mg group) an 
increase of at least 50% in creatine level was reported were 
reported during a 6 months’ period in a study,30 but it should 
be noted that the highest creatine level was within the normal 
range. Similar findings were found in Fleischmann et al29 and 
Kremer et al,34 in which four and five patients, respectively, 
experienced 50% increase in creatine level in the tofacitinib 
groups. At week 24, elevation of serum creatine 30% or 
0.2 mg/dL was noted in 20.5 and 21.6% of patients treated 
with tofacitinib 5 and 10 mg, respectively.34 In a long-term 
observation period of 24 months, 33% elevation of creatine 
level was observed in 9.5 and 9.6% of patients treated with 
tofacitinib 5 and 10 mg, respectively, while 50% elevation 
of creatine level was observed in 1.6 and 2.8%.35 Continuing 
tofacitinib treatment in LTE study results in the stabilization 
of serum creatine level up to 288 weeks (Table 3).38
Other AEs of special interest
Although special attention was given to gastrointestinal 
perforations as AEs during DMARD treatment,40 only one 
case of temporary discontinuation of treatment due to gastro-
intestinal bleeding in a patient receiving tofacitinib at a dose 
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of 3 mg BID was described.29 Data from LTE studies lasting 
up to 8.5 years also revealed a low risk of gastrointestinal 
perforations associated with tofacitinib treatment.40 In several 
studies, an increase in aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) levels was reported among 
the RA24,27,34,35 patients treated with tofacitinib. In most RCT 
trials, an increase in AST or ALT levels three times above 
the normal range was rare,24,27,30,35 and occurred in single 
cases with a spontaneous return to normal levels, without 
association with study duration.24 A similar risk for increased 
aminotransferase levels was reported for patients treated with 
tofacitinib at a dose of 5 and 10 mg BID and MTX during 
long-term follow-up of 24 months.35 In contrast, elevated 
ALT and AST levels were the most common AEs reported 
up to 12 weeks (5% in all treatment groups) in studies by 
Kremer et al34 and Tanaka et al,36 where the incidence of 
elevated ALT was up to 22.2% and the incidence of elevated 
AST was up to 14.8% in the group receiving tofacitinib at 
a dose of 5 mg BID. Discontinuation of treatment due to 
increased AST or ALT levels was rare and reported only in 
three cases.32
Patient-focused perspectives such 
as quality of life and patient’s 
satisfaction, acceptability, and 
adherence
Patients with active RA treated with tofacitinib combined 
with conventional DMARD therapy reported significant, 
sustained, and clinically meaningful improvements in patient-
related outcomes (PROs) compared to placebo. Statistically 
significant improvements from baseline vs placebo were 
recorded at month 3 and sustained to 12 months after initia-
tion of the therapy, in a number of domains relating to all 
eight SF-36 domains with tofacitinib 10 mg BID and seven 
SF-36 domains with tofacitinib 5 mg BID. Significantly, 
more tofacitinib-treated patients reported improvements 
greater than or equal to the minimum clinically important 
differences at month 3 vs placebo in all PROs, except the 
SF-36 role-emotional domain (results were significant for 
tofacitinib 10 mg BID).57
Two double blind, placebo-controlled studies58 evaluated 
patients with inadequate response to MTX who received 
tofacitinib 1–15 mg BID or 20 mg once daily or placebo, in 
a number of life quality domains; significant improvements 
vs placebo were observed at week 12. In the monotherapy 
study (n=384), significant improvements in the quality of life 
were reported at week 12 for tofacitinib 5 and 10 mg BID. 
In both studies, improvements in several domains of the 
SF-36 in the tofacitinib groups were seen at weeks 12 and 24. 
Tofacitinib, either in combination with MTX or as mono-
therapy, demonstrated rapid and sustained improvement in 
health-related quality of life.58
At month 3, tofacitinib 10 mg BID treatment resulted in 
significant changes from baseline vs placebo across all PROs, 
sustained to month 12, with the highest number of patients 
reporting improvements, at least of minimum clinically impor-
tant differences, vs placebo. Changes from baseline at month 3 
with tofacitinib 5 mg BID and adalimumab were similar and 
statistically significant compared to placebo across most 
patient-related outcomes; in the SF-36 Mental Component 
Score and Social Functioning, Role Emotional, and Mental 
Health domains, significantly more patients reported rel-
evant improvements compared to placebo. Patients with 
moderate-to-severe RA and inadequate responses to MTX 
reported significant improvements across a broad range of 
PROs with tofacitinib 5 and 10 mg BID and adalimumab, 
that were significantly superior to placebo.59
In another study, it was revealed that tofacitinib was 
more commonly used as monotherapy and yielded at least 
comparable persistence and adherence as to adalimumab, 
etanercept, and abatacept.60
Tofacitinib, an oral drug, provides patients an alternative 
to the subcutaneously or intravenously administered biologic 
DMARDs route; it should be preferred as a more convenient 
and easier way of drug administration. It was confirmed that, 
in a survey completed by 380 patients with RA, the majority 
(56.4%) of patients prefer oral administration of drugs rather 
than parenteral and suggest that it could be a more attractive 
and accepted way of treatment among RA patients.61
Conclusions, place in therapy
Tofacitinib is a drug with a different mechanism of action 
than other products approved for the treatment of RA and 
may be considered as a therapeutic option in some patients. 
Regardless of its mechanism of action, the oral administration 
route might be preferred by some patients. Randomized con-
trolled studies revealed a significant benefit over placebo in 
terms of the efficacy outcomes (ACR20 and ACR50 response 
rates), and clinically significant improvements in PROs were 
reported compared with placebo. Clinical trials on tofacitinib 
reported an increased risk of infections, including serious 
infections; therefore, strict and rigorous monitoring is required 
especially in patients older than 65 years. Further studies, 
especially in a clinical practice setting, are necessary to better 
understand the efficacy and safety profile of tofacitinib.
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